⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LRMR News
Larimar Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
LRMR
Form 8-K
sec.gov
LRMR
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
globenewswire.com
LRMR
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
globenewswire.com
LRMR
Form 8-K
sec.gov
LRMR
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
LRMR
Form 8-K
sec.gov
LRMR
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
globenewswire.com
LRMR
Form 8-K
sec.gov
LRMR
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
globenewswire.com
LRMR